A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance.
Black or African American
/ genetics
Alternative Splicing
Animals
Cell Line, Tumor
Docetaxel
/ pharmacology
Drug Resistance, Neoplasm
Humans
Male
PC-3 Cells
Phenotype
Prostatic Neoplasms
/ drug therapy
RNA Splicing
Rabbits
Receptor, Fibroblast Growth Factor, Type 3
/ genetics
Signal Transduction
Survival Analysis
Transfection
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
18
04
2019
revised:
19
06
2019
accepted:
21
06
2019
pubmed:
4
7
2019
medline:
17
7
2020
entrez:
4
7
2019
Statut:
ppublish
Résumé
Alternative splicing (AS) has been shown to participate in prostate cancer development and progression; however, a link between AS and prostate cancer health disparities has been largely unexplored. Here we report on the cloning of a novel splice variant of
Identifiants
pubmed: 31266816
pii: 1541-7786.MCR-19-0415
doi: 10.1158/1541-7786.MCR-19-0415
pmc: PMC6886680
mid: NIHMS1533145
doi:
Substances chimiques
Docetaxel
15H5577CQD
FGFR3 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2115-2125Subventions
Organisme : NCI NIH HHS
ID : R01 CA204806
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD084633
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103457
Pays : United States
Organisme : NIEHS NIH HHS
ID : K01 ES025434
Pays : United States
Organisme : NIGMS NIH HHS
ID : SC1 GM127256
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Cancer Res. 2002 Nov 15;62(22):6659-66
pubmed: 12438264
FEBS Lett. 1993 Sep 20;330(3):249-52
pubmed: 8375495
BMC Bioinformatics. 2011 Jul 27;12:305
pubmed: 21794104
Mol Med Rep. 2017 Dec;16(6):9035-9042
pubmed: 29039490
Oncotarget. 2016 Jan 19;7(3):2721-33
pubmed: 26517680
Cancer Biol Ther. 2007 Jul;6(7):1121-9
pubmed: 17611409
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
Clin Cancer Res. 2016 Apr 1;22(7):1744-56
pubmed: 26553749
EMBO J. 1996 Feb 1;15(3):520-7
pubmed: 8599935
Blood. 2011 Nov 10;118(19):5250-4
pubmed: 21908430
Oncotarget. 2017 Sep 6;8(44):77567-77585
pubmed: 29100409
Cancer Res Treat. 2018 Oct;50(4):1252-1259
pubmed: 29334610
Nat Commun. 2017 Jun 30;8:15921
pubmed: 28665395
Nat Rev Urol. 2009 Aug;6(8):454-60
pubmed: 19657379
Cancer Res. 2016 Jul 15;76(14):4205-15
pubmed: 27267910
CA Cancer J Clin. 2016 Jul;66(4):290-308
pubmed: 26910411
Mod Pathol. 2009 Jun;22(6):848-56
pubmed: 19377444
Cancer. 2017 Oct 15;123(20):3925-3932
pubmed: 28657667
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Sci Transl Med. 2014 Sep 3;6(252):252ra122
pubmed: 25186177
Nature. 2011 Nov 23;480(7377):387-90
pubmed: 22113612
Nat Med. 2012 Mar 18;18(4):521-8
pubmed: 22426421
Mol Cancer Ther. 2008 Dec;7(12):3834-41
pubmed: 19056677
Mol Oncol. 2018 Jun;12(7):1138-1152
pubmed: 29741809
Int J Clin Exp Med. 2015 Nov 15;8(11):20778-86
pubmed: 26885001
Nucleic Acids Res. 2016 Jan 4;44(D1):D1018-22
pubmed: 26602693
Lung Cancer. 2016 Feb;92:41-6
pubmed: 26775595
Mol Cell. 2006 Mar 3;21(5):711-7
pubmed: 16507368
Cancer Lett. 2018 Mar 1;416:24-30
pubmed: 29246644
Cancers (Basel). 2018 Nov 20;10(11):null
pubmed: 30463359
Int J Cancer. 2008 Jul 15;123(2):430-435
pubmed: 18452170
Urol Oncol. 2018 Aug;36(8):365.e15-365.e26
pubmed: 29887238
Transl Oncol. 2017 Jun;10(3):357-366
pubmed: 28342996
Phytother Res. 2014 Mar;28(3):423-31
pubmed: 23686889
Oncotarget. 2017 Jan 24;8(4):6179-6192
pubmed: 28008155
Nat Commun. 2016 Jan 04;7:10262
pubmed: 26725515
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Pathobiology. 2010;77(5):249-52
pubmed: 21116115
Oncotarget. 2016 Apr 26;7(17):24252-68
pubmed: 26992226
Neoplasia. 2013 Aug;15(8):975-88
pubmed: 23908597
J Clin Oncol. 2013 Aug 20;31(24):2979-80
pubmed: 23878300
Crit Rev Oncol Hematol. 2017 May;113:256-267
pubmed: 28427515
PLoS One. 2015 Jul 16;10(7):e0133165
pubmed: 26182292
Oncotarget. 2016 Mar 22;7(12):14394-404
pubmed: 26887047
Prostate. 2011 May;71(6):637-41
pubmed: 20957671
Int J Oncol. 2010 Dec;37(6):1477-82
pubmed: 21042716
Clin Cancer Res. 2019 Jan 15;25(2):463-472
pubmed: 30242023
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Mol Cell Probes. 2003 Apr-Jun;17(2-3):55-7
pubmed: 12788025
EBioMedicine. 2015 Mar 1;2(3):194-204
pubmed: 26097890